(BUSINESS WIRE)--BG Medicine, a life sciences company focused on the discovery, development, and commercialization of novel diagnostics, today announced the publication* of a study exploring the predictive value of plasma galectin-3 levels in heart failure (HF) patients with reduced and preserved ejection fraction.
